LWANC
AKBA icon

Laurel Wealth Advisors (North Carolina)’s Akebia Therapeutics AKBA Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-229
Closed -$234 – 701
2024
Q2 		$234 Buy
+229
New +$283 ﹤0.01% 625

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s AKBA Position: Q3 2024 in Review

Laurel Wealth Advisors (North Carolina) sold out of Akebia Therapeutics (AKBA) in Q3 2024, closing a stake of 229 shares — an estimated $234 sold.

Laurel Wealth Advisors (North Carolina) first reported a position in AKBA in Q2 2024 and held it in 1 quarter. The position peaked at $234 in Q2 2024. 114 funds tracked by Wall St. Rank hold AKBA as of Q3 2024.

  • Laurel Wealth Advisors (North Carolina) reported no remaining Akebia Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Laurel Wealth Advisors (North Carolina) sold 229 Akebia Therapeutics shares in Q3 2024, an estimated $234.
  • Laurel Wealth Advisors (North Carolina) first reported a position in Akebia Therapeutics in Q2 2024 and held it in 1 quarter.
  • Laurel Wealth Advisors (North Carolina)'s Akebia Therapeutics position peaked at $234 in Q2 2024.
  • 114 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2024.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q3 2024, filed 5 Nov 2024.